Discovery of small-molecule ATR inhibitors for potential cancer treatment: a patent review from 2014 to present.
Fiche publication
Date publication
janvier 2022
Journal
Expert opinion on therapeutic patents
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen
Tous les auteurs :
Hu S, Hui Z, Duan J, Garrido C, Xie T, Ye XY
Lien Pubmed
Résumé
Ataxia telangiectasia and RAD3-related kinase (ATR) is one of the key PIKKs family members important for DNA damage response and repair pathways. Targeting ATR kinase for potential cancer therapy has attracted a great deal of attention to both pharmaceutical industries and academic community.
Mots clés
DNA damage response (DDR), ataxia telangiectasia and RAD3-related kinase (ATR), cancer therapy, inhibitor, patent review
Référence
Expert Opin Ther Pat. 2022 Jan 10;: